Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.

Oncoimmunology·2026
Same author

The Role of MNX1-AS1 in Ovarian Cancer Resistance and Tumor Progression via RNA-RNA Interactions.

International journal of molecular sciences·2026
Same author

Drug Repurposing Uncovers New Chemical Scaffolds as Potent Urease Inhibitors: A Comprehensive Computational Study.

International journal of molecular sciences·2026
Same author

Phase I trial of a heat-conditioned tumor lysate vaccine (TRIMELVax) in anti-PD-1 refractory melanoma: safety and immunological aspects (NCT06556004).

British journal of cancer·2026
Same author

Interplay between the arachidonic acid/cyclooxygenase 2/prostaglandin E<sub>2</sub> pathway and RNA viral infections.

Expert review of anti-infective therapy·2026
Same author

Associations between survey completion mode and sociodemographic factors among individuals eligible for lung cancer screening.

Journal of clinical and translational science·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
04:49

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research

Published on: May 5, 2021

6.3K

Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy.

Pablo A Palacios1, Iván Flores2, Lucas Cereceda1

  • 1Millennium Institute on Immunology and Immunotherapy, Programa de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.

Cancers
|February 13, 2025
PubMed
Summary
This summary is machine-generated.

Patient-derived organoids (PDOs) offer a promising model to study how invariant natural killer T (iNKT) cells fight tumors. These models help overcome the immunosuppressive tumor microenvironment to advance cancer immunotherapy.

Keywords:
3D cancer modelsimmunotherapyinvariant Natural Killer T cells (iNKT)patient-derived organoid (PDO)tumor microenvironment (TME)

More Related Videos

Establishment and Culture of Patient-Derived Breast Organoids
08:29

Establishment and Culture of Patient-Derived Breast Organoids

Published on: February 17, 2023

4.4K
Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

1.3K

Related Experiment Videos

Last Updated: Jun 24, 2026

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research
04:49

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research

Published on: May 5, 2021

6.3K
Establishment and Culture of Patient-Derived Breast Organoids
08:29

Establishment and Culture of Patient-Derived Breast Organoids

Published on: February 17, 2023

4.4K
Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

1.3K

Area of Science:

  • Immunology
  • Cancer Biology
  • Biotechnology

Background:

  • Invariant Natural Killer T (iNKT) cells bridge innate and adaptive immunity, exhibiting potent anti-tumor activities.
  • The tumor microenvironment (TME) often suppresses iNKT cell function through immunosuppressive cells and factors.
  • Patient-derived organoids (PDOs) accurately recapitulate primary tumor characteristics, offering a valuable preclinical model.

Purpose of the Study:

  • To explore the utility of PDO platforms for studying iNKT cell interactions within the TME.
  • To evaluate strategies for enhancing iNKT cell anti-tumor efficacy in a tumor-mimicking environment.
  • To investigate the potential of PDO-iNKT platforms for personalized cancer immunotherapy research.

Main Methods:

  • Integration of iNKT cells into patient-derived organoid models.
  • Investigation of CD1d-mediated interactions and Th1-biased responses.
  • Assessment of combination therapies, including immune checkpoint inhibitors.
  • Evaluation of metabolic modulation strategies to enhance iNKT cell activity.
  • Utilizing emerging technologies like organoid-on-a-chip and multi-omics.

Main Results:

  • PDOs effectively model tumor-immune dynamics, including interactions with iNKT cells.
  • The platform allows for the assessment of various strategies to overcome TME-induced immunosuppression.
  • PDO-iNKT systems show potential for evaluating novel therapeutic combinations and metabolic interventions.
  • Emerging technologies enhance the capabilities of PDO-iNKT platforms for complex biological studies.

Conclusions:

  • PDO-iNKT platforms represent a powerful tool for dissecting TME-mediated immunosuppression and optimizing iNKT cell-based cancer therapies.
  • These models hold significant promise for bridging the gap between preclinical research and clinical translation in personalized immunotherapy.
  • Further development of PDO-iNKT systems can accelerate the advancement of effective cancer treatments.